FARESTON

This brand name is authorized in Austria, Australia, Estonia, Finland, France, Croatia, Ireland, Japan, Lithuania, Poland, Romania, United Kingdom, United States, South Africa

Active ingredients

The drug FARESTON contains one active pharmaceutical ingredient (API):

1 Toremifene UNII 2498Y783QT - TOREMIFENE CITRATE

Toremifene is a nonsteroidal triphenylethylene derivative that binds to estrogen receptors and may produce estrogenic, anti-estrogenic or both effects, depending upon the duration of treatment, animal species, gender, target organ and variable selected. Toremifene is indicated in first line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients. Read about Toremifene

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
FARESTON Tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L02BA02	Toremifene	L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents → L02BA Anti-estrogens
Discover more medicines within L02BA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 8216K
Country: EE	Ravimiamet	Identifier(s): 1199943, 1199954
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 409391
Country: FR	Base de données publique des médicaments	Identifier(s): 60433369
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 41241
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291007F1021, 4291007F2028
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1028395, 1028396
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100119672
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W51515001, W51515002
Country: US	FDA, National Drug Code	Identifier(s): 42747-327
Country: ZA	Health Products Regulatory Authority	Identifier(s): 31/21.12/0339